The multiple functions and mechanisms of osteopontin

Clinical Biochemistry

Volumn 59, Issue , 2018, Pages 17-24

  Icer, Mehmet Arif ^a   Gezmen Karadag, Makbule ^a  

^a GAZI UNIVERSITY   (Turkey)

Author keywords

Biomarker; Cancer; Medicinal biochemistry; Obesity; Osteopontin

Indexed keywords

OSTEOPONTIN; BIOLOGICAL MARKER; TUMOR NECROSIS FACTOR;

BIOMINERALIZATION; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; HEALTH; HUMAN; INFLAMMATION; MALIGNANT NEOPLASM; NEPHROLITHIASIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SECRETION; PROTEIN STRUCTURE; REVIEW; WOUND HEALING; ANIMAL; ARTHROPATHY; ATHEROSCLEROTIC PLAQUE; BLOOD; CALCINOSIS; FRACTURE; MACROPHAGE; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION; T LYMPHOCYTE; URINE; VASCULAR DISEASE;

ANIMALS; BIOMARKERS; CALCINOSIS; FRACTURES, BONE; HUMANS; JOINT DISEASES; MACROPHAGES; OSTEOPONTIN; PLAQUE, ATHEROSCLEROTIC; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR DISEASES;

EID: 85049754803     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2018.07.003     Document Type: Review

References (105)

1. Karpinsky, G., Fatyga, A., Krawczyk, M.A., Chamera, M., Sande, N., Szmyd, D., Izycka-Swieszewska, E., Bien, E., Osteopontin: its potential role in cancer of children and young adults. Biomark. Med 11:4 (2017), 389–402.
2. Clemente, N., Raineri, D., Cappellano, G., Boggio, E., Favero, F., Soluri, M.F., Dianzani, C., Comi, C., Dianzani, U., Chiocchetti, A., Osteopontin bridging innate and adaptive immunity in autoimmune diseases. J Immunol Res, 2016, 2016.
3. Franzen, A., Heinegård, D., Isolation and characterization of two sialoproteins present only in bone calcified matrix. Biochem. J. 232:3 (1985), 715–724.
4. Mazzali, M., Kipari, T., Ophascharoensuk, V., Wesson, J., Johnson, R., Hughes, J., Osteopontin—a molecule for all seasons. QJM 95:1 (2002), 3–13.
5. Chen, Q., Shou, P., Zhang, L., Xu, C., Zheng, C., Han, Y., Li, W., Huang, Y., Zhang, X., Shao, C., An osteopontin-integrin interaction plays a critical role in directing adipogenesis and osteogenesis by mesenchymal stem cells. Stem Cells 32:2 (2014), 327–337.
6. Yoshitake, H., Rittling, S.R., Denhardt, D.T., Noda, M., Osteopontin-deficient mice are resistant to ovariectomy-induced bone resorption. Proc. Natl. Acad. Sci. 96:14 (1999), 8156–8160.
7. Ashkar, S., Weber, G.F., Panoutsakopoulou, V., Sanchirico, M.E., Jansson, M., Zawaideh, S., Rittling, S.R., Denhardt, D.T., Glimcher, M.J., Cantor, H., Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science 287:5454 (2000), 860–864.
8. Giachelli, C.M., Steitz, S., Osteopontin: a versatile regulator of inflammation and biomineralization. Matrix Biol. 19:7 (2000), 615–622.
9. Berezin, A., Kremzer, A., Circulating osteopontin as a marker of early coronary vascular calcification in type two diabetes mellitus patients with known asymptomatic coronary artery disease. Atherosclerosis 229:2 (2013), 475–481.
10. Wesson, J.A., Johnson, R.J., Mazzali, M., Beshensky, A.M., Stietz, S., Giachelli, C., Liaw, L., Alpers, C.E., Couser, W.G., Kleinman, J.G., Osteopontin is a critical inhibitor of calcium oxalate crystal formation and retention in renal tubules. J. Am. Soc. Nephrol. 14:1 (2003), 139–147.
11. Rangaswami, H., Bulbule, A., Kundu, G.C., Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol. 16:2 (2006), 79–87.
12. Wai, P.Y., Kuo, P.C., The role of osteopontin in tumor metastasis. J. Surg. Res. 121:2 (2004), 228–241.
13. Nomiyama, T., Perez-Tilve, D., Ogawa, D., Gizard, F., Zhao, Y., Heywood, E.B., Jones, K.L., Kawamori, R., Cassis, L.A., Tschöp, M.H., Osteopontin mediates obesity-induced adipose tissue macrophage infiltration and insulin resistance in mice. J. Clin. Invest. 117:10 (2007), 2877–2888.
14. Matsuzaki, H., Katsumata, S.I., Uehara, M., Suzuki, K., Miwa, M., High-phosphorus diet induces osteopontin expression of renal tubules in rats. J. Clin. Biochem. Nutr. 41:3 (2007), 179–183.
15. Wang, X., Cheng, M., Zhao, M., Ge, A., Guo, F., Zhang, M., Yang, Y., Liu, L., Yang, N., Differential effects of high-fat-diet rich in lard oil or soybean oil on osteopontin expression and inflammation of adipose tissue in diet-induced obese rats. Eur. J. Nutr. 52:3 (2013), 1181–1189.
16. Singh, A., Pezeshki, A., Zapata, R.C., Yee, N.J., Knight, C.G., Tuor, U.I., Chelikani, P.K., Diets enriched in whey or casein improve energy balance and prevent morbidity and renal damage in salt-loaded and high-fat-fed spontaneously hypertensive stroke-prone rats. J. Nutr. Biochem. 37 (2016), 47–59.
17. Lund, S.A., Giachelli, C.M., Scatena, M., The role of osteopontin in inflammatory processes. J. Cell Commun. Signal. 3:3–4 (2009), 311–322.
18. Standal, T., Borset, M., Sundan, A., Role of osteopontin in adhesion, migration, cell survival and bone remodeling. Exp. Oncol. 26:3 (2004), 179–184.
19. Denhardt, D.T., Guo, X., Osteopontin: a protein with diverse functions. FASEB J. 7:15 (1993), 1475–1482.
20. Denhardt, D.T., Noda, M., Osteopontin expression and function: role in bone remodeling. J. Cell. Biochem. 72:S30–31 (1998), 92–102.
21. Chackalaparampil, I., Peri, A., Nemir, M., Mckee, M.D., Lin, P.-H., Mukherjee, B.B., Mukherjee, A.B., Cells in vivo and in vitro from osteopetrotic mice homozygous for c-src disruption show suppression of synthesis of osteopontin, a multifunctional extracellular matrix protein. Oncogene 12:7 (1996), 1457–1467.
22. Coppola, D., Szabo, M., Boulware, D., Muraca, P., Alsarraj, M., Chambers, A.F., Yeatman, T.J., Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin. Cancer Res. 10:1 (2004), 184–190.
23. Ophascharoensuk, V., Giachelli, C.M., Gordon, K., Hughes, J., Pichler, R., Brown, P., Liaw, L., Schmidt, R., Shankland, S.J., Alpers, C.E., Obstructive uropathy in the mouse: role of osteopontin in interstitial fibrosis and apoptosis. Kidney Int. 56:2 (1999), 571–580.
24. Liu, C.-C., Huang, S.-P., Tsai, L.-Y., Wu, W.-J., Juo, S.-H.H., Chou, Y.-H., Huang, C.-H., Wu, M.-T., The impact of osteopontin promoter polymorphisms on the risk of calcium urolithiasis. Clin. Chim. Acta 411:9 (2010), 739–743.
25. Şentürk, N., Kütanöz inflamasyon. Archiv. Turkish Dermatol. Venerol. Turkderm 47:1 (2013), 27–36.
26. Nau, G.J., Liaw, L., Chupp, G.L., Berman, J.S., Hogan, B.L., Young, R.A., Attenuated host resistance against mycobacterium bovis BCG infection in mice lacking osteopontin. Infect. Immun. 67:8 (1999), 4223–4230.
27. Gómez-Ambrosi, J., Catalán, V., Ramírez, B., Rodríguez, A., Colina, I., Silva, C., Rotellar, F., Mugueta, C., Gil, MaJ, Cienfuegos, J.A., Plasma osteopontin levels and expression in adipose tissue are increased in obesity. J. Clin. Endocrinol. Metabol. 92:9 (2007), 3719–3727.
28. Kiefer, F.W., Zeyda, M., Todoric, J., Huber, J., Geyeregger, R., Weichhart, T., Aszmann, O., Ludvik, B., Silberhumer, G.R., Prager, G., Osteopontin expression in human and murine obesity: extensive local up-regulation in adipose tissue but minimal systemic alterations. Endocrinology 149:3 (2008), 1350–1357.
29. Schaller, G., Aso, Y., Schernthaner, G.-H., Kopp, H.-P., Inukai, T., Kriwanek, S., Schernthaner, G., Increase of osteopontin plasma concentrations after bariatric surgery independent from inflammation and insulin resistance. Obes. Surg., 19(3), 2009, 351.
30. Nau, G.J., Guilfoile, P., Chupp, G.L., Berman, J.S., Kim, S.J., Kornfeld, H., Young, R.A., A chemoattractant cytokine associated with granulomas in tuberculosis and silicosis. Proc. Natl. Acad. Sci. 94:12 (1997), 6414–6419.
31. Nau, G.J., Chupp, G.L., Emile, J.-F., Jouanguy, E., Berman, J.S., Casanova, J.-L., Young, R.A., Osteopontin expression correlates with clinical outcome in patients with mycobacterial infection. Am. J. Pathol. 157:1 (2000), 37–42.
32. 泉啓介: Baseline serum osteopontin levels predict the clinical effectiveness of tocilizumab but not infliximab in biologic-naïve patients with rheumatoid arthritis: a single-center prospective study at 1 year: the Keio First-Bio Cohort Study. 慶應義塾大学; 2016.
33. Iida, T., Wagatsuma, K., Hirayama, D., Nakase, H., Is osteopontin a friend or foe of cell apoptosis in inflammatory gastrointestinal and liver diseases?. Int. J. Mol. Sci., 19(1), 2017, 7.
34. Lenton, S., Seydel, T., Nylander, T., Holt, C., Härtlein, M., Teixeira, S., Zaccai, G., Dynamic footprint of sequestration in the molecular fluctuations of osteopontin. J. R. Soc. Interface, 12(110), 2015, 20150506.
35. Reinholt, F.P., Hultenby, K., Oldberg, A., Heinegård, D., Osteopontin–a possible anchor of osteoclasts to bone. Proc. Natl. Acad. Sci. 87:12 (1990), 4473–4475.
36. Ross, F.P., Chappel, J., Alvarez, J., Sander, D., Butler, W., Farach-Carson, M., Mintz, K., Robey, P.G., Teitelbaum, S., Cheresh, D., Interactions between the bone matrix proteins osteopontin and bone sialoprotein and the osteoclast integrin alpha v beta 3 potentiate bone resorption. J. Biol. Chem. 268:13 (1993), 9901–9907.
37. McKee, M., Nanci, A., Osteopontin at mineralized tissue interfaces in bone, teeth, and osseointegrated implants: ultrastructural distribution and implications for mineralized tissue formation, turnover, and repair. Microsc. Res. Tech. 33:2 (1996), 141–164.
38. Liaw, L., Birk, D.E., Ballas, C.B., Whitsitt, J.S., Davidson, J.M., Hogan, B.L., Altered wound healing in mice lacking a functional osteopontin gene (spp1). J. Clin. Investig., 101(7), 1998, 1468.
39. Rittling, S.R., Matsumoto, H.N., Mckee, M.D., Nanci, A., An, X.R., Novick, K.E., Kowalski, A.J., Noda, M., Denhardt, D.T., Mice lacking osteopontin show normal development and bone structure but display altered osteoclast formation in vitro. J. Bone Miner. Res. 13:7 (1998), 1101–1111.
40. Chellaiah, M.A., Soga, N., Swanson, S., McAllister, S., Alvarez, U., Wang, D., Dowdy, S.F., Hruska, K.A., Rho-A is critical for osteoclast podosome organization, motility, and bone resorption. J. Biol. Chem. 275:16 (2000), 11993–12002.
41. Giachelli, C.M., Bae, N., Almeida, M., Denhardt, D.T., Alpers, C.E., Schwartz, S.M., Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques. J. Clin. Investig., 92(4), 1993, 1686.
42. Steitz, S.A., Speer, M.Y., Curinga, G., Yang, H.-Y., Haynes, P., Aebersold, R., Schinke, T., Karsenty, G., Giachelli, C.M., Smooth muscle cell phenotypic transition associated with calcification. Circ. Res. 89:12 (2001), 1147–1154.
43. Leali, D., Dell'Era, P., Stabile, H., Sennino, B., Chambers, A.F., Naldini, A., Sozzani, S., Nico, B., Ribatti, D., Presta, M., Osteopontin (Eta-1) and fibroblast growth factor-2 cross-talk in angiogenesis. J. Immunol. 171:2 (2003), 1085–1093.
44. McIntosh, C.H., Widenmaier, S., Kim, S.-J., Pleiotropic actions of the incretin hormones. Vitamins & Hormones, 84, 2010, Elsevier, 21–79.
45. Lyssenko, V., Eliasson, L., Kotova, O., Pilgaard, K., Wierup, N., Salehi, A., Wendt, A., Jonsson, A., De Marinis, Y.Z., Berglund, L.M., Pleiotropic effects of GIP on islet function involve osteopontin. Diabetes 60:9 (2011), 2424–2433.
46. Nitz, I., Fisher, E., Weikert, C., Burwinkel, B., Li, Y., Möhlig, M., Boeing, H., Schreiber, S., Schrezenmeir, J., Döring, F., Association analyses of GIP and GIPR polymorphisms with traits of the metabolic syndrome. Mol. Nutr. Food Res. 51:8 (2007), 1046–1052.
47. Berglund, L.M., Lyssenko, V., Ladenvall, C., Kotova, O., Edsfeldt, A., Pilgaard, K., Alkayyali, S., Brøns, C., Forsblom, C., Jonsson, A., Glucose-dependent insulinotropic polypeptide (GIP) stimulates osteopontin expression in the vasculature via endothelin-1 and CREB. Diabetes 65:1 (2015), 239–254.
48. Omar, B., Banke, E., Guirguis, E., Åkesson, L., Manganiello, V., Lyssenko, V., Groop, L., Gomez, M.F., Degerman, E., Regulation of the pro-inflammatory cytokine osteopontin by GIP in adipocytes–a role for the transcription factor NFAT and phosphodiesterase 3B. Biochem. Biophys. Res. Commun. 425:4 (2012), 812–817.
49. Beadenkopf, W., Calcification in the coronary arteries and its relationship to arteriosclerosis and myocardial infarction. Am. J. Roentgenol. Radium Therapy, Nucl. Med. 92 (1964), 865–871.
50. Fitzpatrick, L., Severson, A., Edwards, W., Ingram, R., Diffuse calcification in human coronary arteries. Association of osteopontin with atherosclerosis. J. Clin. Invest., 94(4), 1994, 1597.
51. Abdalrhim, A.D., Marroush, T.S., Austin, E.E., Gersh, B.J., Solak, N., Rizvi, S.A., Bailey, K.R., Kullo, I.J., Plasma Osteopontin levels and adverse cardiovascular outcomes in the PEACE trial. PLoS One, 11(6), 2016, e0156965.
52. Dimitrow, P.P., Jawien, M., Gackowski, A., The influence of statins on levels of calcification biomarkers in patients with aortic sclerosis or mild aortic stenosis. J. Heart Valve Dis., 20(1), 2011.
53. Srivatsa, S., Harrity, P., Maercklein, P., Kleppe, L., Veinot, J., Edwards, W., Johnson, C., Fitzpatrick, L., Increased cellular expression of matrix proteins that regulate mineralization is associated with calcification of native human and porcine xenograft bioprosthetic heart valves. J. Clin. Investig., 99(5), 1997, 996.
54. Pritzker, L., Scatena, M., Giachelli, C., The role of osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand in human microvascular endothelial cell survival. Mol. Biol. Cell 15:6 (2004), 2834–2841.
55. Kurban, S., Mehmetoglu, I., Osteoprotegerin, RANK and RANK ligand. Turkish J. Biochem. 32:4 (2007), 178–184.
56. McKee, M.D., Pedraza, C.E., Kaartinen, M.T., Osteopontin and wound healing in bone. Cells Tissues Organs 194:2–4 (2011), 313–319.
57. Lin, Y.-H., Huang, C.-J., Chao, J.-R., Chen, S.-T., Lee, S.-F., Yen, J.J.-Y., Yang-Yen, H.-F., Coupling of osteopontin and its cell surface receptor CD44 to the cell survival response elicited by interleukin-3 or granulocyte-macrophage colony-stimulating factor. Mol. Cell. Biol. 20:8 (2000), 2734–2742.
58. Lenga, Y., Koh, A., Perera, A.S., McCulloch, C.A., Sodek, J., Zohar, R., Osteopontin expression is required for myofibroblast differentiation. Circ. Res. 102:3 (2008), 319–327.
59. Brown, L.F., Papadopoulos-Sergiou, A., Berse, B., Manseau, E.J., Tognazzi, K., Perruzzi, C.A., Dvorak, H.F., Senger, D.R., Osteopontin expression and distribution in human carcinomas. Am. J. Pathol., 145(3), 1994, 610.
60. Guo, X., Zhang, Y.P., Mitchell, D.A., Denhardt, D.T., Chambers, A.F., Identification of a ras-activated enhancer in the mouse osteopontin promoter and its interaction with a putative ETS-related transcription factor whose activity correlates with the metastatic potential of the cell. Mol. Cell. Biol. 15:1 (1995), 476–487.
61. Correa, P., Haenszel, W., Cuello, C., Zavala, D., Fontham, E., Zarama, G., Tannenbaum, S., Collazos, T., Ruiz, B., Gastric precancerous process in a high risk population: cohort follow-up. Cancer Res. 50:15 (1990), 4737–4740.
62. Chang, W.L., Yang, H.B., Cheng, H.C., Chuang, C.H., Lu, P.J., Sheu, B.S., Increased gastric osteopontin expression by helicobacter pylori infection can correlate with more severe gastric inflammation and intestinal metaplasia. Helicobacter 16:3 (2011), 217–224.
63. Flamant, S., Kortulewski, T., Dugray, A., Bonnet, M.-L., Guillier, M., Guilhot, F., Bourhis, J.-H., Vainchenker, W., Tronik-Le Roux, D., Turhan, A., Osteopontin is upregulated by BCR-ABL. Biochem. Biophys. Res. Commun. 333:4 (2005), 1378–1384.
64. Lee, J.-L., Wang, M.-J., Sudhir, P.-R., Chen, G.-D., Chi, C.-W., Chen, J.-Y., Osteopontin promotes integrin activation through outside-in and inside-out mechanisms: OPN-CD44V interaction enhances survival in gastrointestinal cancer cells. Cancer Res. 67:5 (2007), 2089–2097.
65. Lee, S.-H., Park, J.-W., Go, D.-M., Kim, H.K., Kwon, H.-J., Han, S.-U., Kim, D.-Y., Ablation of osteopontin suppresses N-methyl-N-nitrosourea and Helicobacter pylori-induced gastric cancer development in mice. Carcinogenesis 36:12 (2015), 1550–1560.
66. Chagan-Yasutan, H., Tsukasaki, K., Takahashi, Y., Oguma, S., Harigae, H., Ishii, N., Zhang, J., Fukumoto, M., Hattori, T., Involvement of osteopontin and its signaling molecule CD44 in clinicopathological features of adult T cell leukemia. Leuk. Res. 35:11 (2011), 1484–1490.
67. Liersch, R., Gerss, J., Schliemann, C., Bayer, M., Schwöppe, C., Biermann, C., Appelmann, I., Kessler, T., Löwenberg, B., Büchner, T., Osteopontin is a prognostic factor for survival of acute myeloid leukemia patients. Blood 119:22 (2012), 5215–5220.
68. Psyrri, A., Kalogeras, K.T., Wirtz, R.M., Kouvatseas, G., Karayannopoulou, G., Goussia, A., Zagouri, F., Veltrup, E., Timotheadou, E., Gogas, H., Association of osteopontin with specific prognostic factors and survival in adjuvant breast cancer trials of the Hellenic Cooperative Oncology Group. J. Transl. Med., 15(1), 2017, 30.
69. Di Bartolomeo, M., Pietrantonio, F., Pellegrinelli, A., Martinetti, A., Mariani, L., Daidone, M.G., Bajetta, E., Pelosi, G., de Braud, F., Floriani, I., Osteopontin, E-cadherin, and β-catenin expression as prognostic biomarkers in patients with radically resected gastric cancer. Gastric Cancer 19:2 (2016), 412–420.
70. Tilli, T., Thuler, L., Matos, A., Coutinho-Camillo, C., Soares, F., da Silva, E., Neves, A., Goulart, L., Gimba, E., Expression analysis of osteopontin mRNA splice variants in prostate cancer and benign prostatic hyperplasia. Exp. Mol. Pathol. 92:1 (2012), 13–19.
71. Mack, P.C., Redman, M.W., Chansky, K., Williamson, S.K., Farneth, N.C., Lara, P.N. Jr., Franklin, W.A., Le, Q.-T., Crowley, J.J., Gandara, D.R., Lower osteopontin plasma levels are associated with superior outcomes in advanced non–small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG study S0003. J. Clin. Oncol. 26:29 (2008), 4771–4776.
72. Debucquoy, A., Goethals, L., Geboes, K., Roels, S., Mc Bride, W.H., Haustermans, K., Molecular responses of rectal cancer to preoperative chemoradiation. Radiother. Oncol. 80:2 (2006), 172–177.
73. Hashiguchi, Y., Tsuda, H., Bandera, C.A., Nishimura, S., Inoue, T., Kawamura, N., Berkowitz, R.S., Mok, S.C., Comparison of osteopontin expression in endometrioid endometrial cancer and ovarian endometrioid cancer. Med. Oncol. 23:2 (2006), 205–212.
74. Huang, J., Pan, C., Hu, H., Zheng, S., Ding, L., Osteopontin-enhanced hepatic metastasis of colorectal cancer cells. PLoS One, 7(10), 2012, e47901.
75. Yan, X., Sano, M., Lu, L., Wang, W., Zhang, Q., Zhang, R., Wang, L., Chen, Q., Fukuda, K., Shen, W., Plasma concentrations of osteopontin, but not thrombin-cleaved osteopontin, are associated with the presence and severity of nephropathy and coronary artery disease in patients with type 2 diabetes mellitus. Cardiovasc. Diabetol., 9(1), 2010, 70.
76. Takemoto, M., Yokote, K., Nishimura, M., Shigematsu, T., Hasegawa, T., Kon, S., Uede, T., Matsumoto, T., Saito, Y., Mori, S., Enhanced expression of osteopontin in human diabetic artery and analysis of its functional role in accelerated atherogenesis. Arterioscler. Thromb. Vasc. Biol. 20:3 (2000), 624–628.
77. Sodhi, C.P., Phadke, S.A., Batlle, D., Sahai, A., Hypoxia and high glucose cause exaggerated mesangial cell growth and collagen synthesis: role of osteopontin. Am. J. Physiol. Renal Physiol. 280:4 (2001), F667–F674.
78. Sun, J., Xu, Y., Deng, H., Sun, S., Dai, Z., Sun, Y., Involvement of osteopontin upregulation on mesangial cells growth and collagen synthesis induced by intermittent high glucose. J. Cell. Biochem. 109:6 (2010), 1210–1221.
79. El-Osta, A., Brasacchio, D., Yao, D., Pocai, A., Jones, P.L., Roeder, R.G., Cooper, M.E., Brownlee, M., Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. J. Exp. Med. 205:10 (2008), 2409–2417.
80. Cai, M., Bompada, P., Atac, D., Laakso, M., Groop, L., De Marinis, Y., Epigenetic regulation of glucose-stimulated osteopontin (OPN) expression in diabetic kidney. Biochem. Biophys. Res. Commun. 469:1 (2016), 108–113.
81. Kim, S.-J., Nian, C., McIntosh, C.H., GIP increases human adipocyte LPL expression through CREB and TORC2-mediated trans-activation of the LPL gene. J. Lipid Res. 51:11 (2010), 3145–3157.
82. Arafat, H.A., Katakam, A.K., Chipitsyna, G., Gong, Q., Vancha, A.R., Gabbeta, J., Dafoe, D.C., Osteopontin protects the islets and β-cells from interleukin-1 β-mediated cytotoxicity through negative feedback regulation of nitric oxide. Endocrinology 148:2 (2007), 575–584.
83. Kim, S.-J., Winter, K., Nian, C., Tsuneoka, M., Koda, Y., McIntosh, C.H., Glucose-dependent insulinotropic polypeptide (GIP) stimulation of pancreatic β-cell survival is dependent upon phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB) signaling, inactivation of the forkhead transcription factor Foxo1, and down-regulation of bax expression. J. Biol. Chem. 280:23 (2005), 22297–22307.
84. Ahlqvist, E., Osmark, P., Kuulasmaa, T., Pilgaard, K., Omar, B., Brøns, C., Kotova, O., Zetterqvist, A.V., Stančáková A., Jonsson, A., Link between GIP and osteopontin in adipose tissue and insulin resistance. Diabetes 62:6 (2013), 2088–2094.
85. Fischer, J.W., Tschöpe, C., Reinecke, A., Giachelli, C.M., Unger, T., Upregulation of osteopontin expression in renal cortex of streptozotocin-induced diabetic rats is mediated by bradykinin. Diabetes 47:9 (1998), 1512–1518.
86. Daniele, G., Mendoza, R.G., Winnier, D., Fiorentino, T., Pengou, Z., Cornell, J., Andreozzi, F., Jenkinson, C., Cersosimo, E., Federici, M., The inflammatory status score including IL-6, TNF-α osteopontin, fractalkine, MCP-1 and adiponectin underlies whole-body insulin resistance and hyperglycemia in type 2 diabetes mellitus. Acta Diabetol. 51:1 (2014), 123–131.
87. Kelly, D.J., Wilkinson-Berka, J.L., Ricardo, S.D., Cox, A.J., Gilbert, R.E., Progression of tubulointerstitial injury by osteopontin-induced macrophage recruitment in advanced diabetic nephropathy of transgenic (mRen-2) 27 rats. Nephrol. Dial. Transplant. 17:6 (2002), 985–991.
88. Kiefer, F.W., Zeyda, M., Gollinger, K., Pfau, B., Neuhofer, A., Weichhart, T., Säemann, M.D., Geyeregger, R., Schlederer, M., Kenner, L., Neutralization of osteopontin inhibits obesity-induced inflammation and insulin resistance. Diabetes 59:4 (2010), 935–946.
89. Takemoto, M., Yokote, K., Yamazaki, M., Ridall, A.L., Butler, W.T., Matsumoto, T., Tamura, K., Saito, Y., Mori, S., Enhanced expression of osteopontin by high glucose in cultured rat aortic smooth muscle cells. Biochem. Biophys. Res. Commun. 258:3 (1999), 722–726.
90. Gordin, D., Forsblom, C., Panduru, N.M., Thomas, M.C., Bjerre, M., Soro-Paavonen, A., Tolonen, N., Sandholm, N., Flyvbjerg, A., Harjutsalo, V., Osteopontin is a strong predictor of incipient diabetic nephropathy, cardiovascular disease, and all-cause mortality in patients with type 1 diabetes. Diabetes Care 37:9 (2014), 2593–2600.
91. Hudkins, K.L., Giachelli, C.M., Cui, Y., Couser, W.G., Johnson, R.J., Alpers, C.E., Osteopontin expression in fetal and mature human kidney. J. Am. Soc. Nephrol. 10:3 (1999), 444–457.
92. Yasui, T., Fujita, K., Hayashi, Y., Ueda, K., Kon, S., Maeda, M., Uede, T., Kohri, K., Quantification of osteopontin in the urine of healthy and stone-forming men. Urol. Res. 27:4 (1999), 225–230.
93. Asplin, J.R., Arsenault, D., Parks, J.H., Coe, F.L., Hoyer, J.R., Contribution of human uropontin to inhibition of calcium oxalate crystallization. Kidney Int. 53:1 (1998), 194–199.
94. Kleinman, J.G., Beshensky, A., Worcester, E.M., Brown, D., Expression of osteopontin, a urinary inhibitor of stone mineral crystal growth, in rat kidney. Kidney Int. 47:6 (1995), 1585–1596.
95. Okada, A., Nomura, S., Saeki, Y., Higashibata, Y., Hamamoto, S., Hirose, M., Itoh, Y., Yasui, T., Tozawa, K., Kohri, K., Morphological conversion of calcium oxalate crystals into stones is regulated by osteopontin in mouse kidney. J. Bone Miner. Res. 23:10 (2008), 1629–1637.
96. Hirose, M., Tozawa, K., Okada, A., Hamamoto, S., Higashibata, Y., Gao, B., Hayashi, Y., Shimizu, H., Kubota, Y., Yasui, T., Role of osteopontin in early phase of renal crystal formation: immunohistochemical and microstructural comparisons with osteopontin knock-out mice. Urol. Res. 40:2 (2012), 121–129.
97. Hamamoto, S., Yasui, T., Okada, A., Hirose, M., Matsui, Y., Kon, S., Sakai, F., Kojima, Y., Hayashi, Y., Tozawa, K., Crucial role of the cryptic epitope SLAYGLR within osteopontin in renal crystal formation of mice. J. Bone Miner. Res. 26:12 (2011), 2967–2977.
98. Asselman, M., Verhulst, A., de Broe, M.E., Verkoelen, C.F., Calcium oxalate crystal adherence to hyaluronan-, osteopontin-, and CD44-expressing injured/regenerating tubular epithelial cells in rat kidneys. J. Am. Soc. Nephrol. 14:12 (2003), 3155–3166.
99. Yaman, F., Aybek, H., Aybek, Z., Üriner sistem taş hastalığı etiyopatogenezinde fetuin-a ve osteopotin. 2011, Pamukkale Üniversitesi.
100. Tawada, T., Fujita, K., Sakakura, T., Shibutani, T., Nagata, T., Iguchi, M., Kohri, K., Distribution of osteopontin and calprotectin as matrix protein in calcium-containing stone. Urol. Res. 27:4 (1999), 238–242.
101. Yasui, T., Fujita, K., Sasaki, S., Sato, M., Sugimoto, M., Hirota, S., Kitamura, Y., Nomura, S., Kohri, K., Expression of bone matrix proteins in urolithiasis model rats. Urol. Res. 27:4 (1999), 255–261.
102. Kleinman, J.G., Wesson, J.A., Hughes, J., Osteopontin and calcium stone formation. Nephron Physiol. 98:2 (2004), p43–p47.
103. Yamate, T., Tsuji, H., Amasaki, N., Iguchi, M., Kurita, T., Kohri, K., Analysis of osteopontin DNA in patients with urolithiasis. Urol. Res. 28:3 (2000), 159–166.
104. Gao, B., Yasui, T., Itoh, Y., Li, Z., Okada, A., Tozawa, K., Hayashi, Y., Kohri, K., Association of osteopontin gene haplotypes with nephrolithiasis. Kidney Int. 72:5 (2007), 592–598.
105. Tsuji, H., Tohru, U., Hirotsugu, U., Masanori, I., Yuji, H., Takashi, K., Urinary concentration of osteopontin and association with urinary supersaturation and crystal formation. Int. J. Urol. 14:7 (2007), 630–634.